Jpmorgan Chase & CO Sigilon Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.74 - $1.64 $74,577 - $165,279	-100,780 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$1.24 - $3.03 $7,126 - $17,413	-5,747 Reduced 5.39%	100,780 $148,000
Q4 2021 Feb 10, 2022	SELL	$2.58 - $6.13 $13,475 - $32,016	-5,223 Reduced 4.67%	106,527 $294,000
Q3 2021 Nov 12, 2021	BUY	$4.42 - $10.61 $493,935 - $1.19 Million	111,750 New	111,750 $632,000

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.